Reviews Nilotinib Capsules


No reviews yet.

Tasigna Capsules Drug Description
Tasigna®
(nilotinib) Capsules

WARNING
QT PROLONGATION AND SUDDEN DEATHS
Tasigna prolongs the QT interval. Sudden deaths have been reported in patients
receiving nilotinib. Tasigna should not be used in patients with hypokalemia,
hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be
corrected prior to Tasigna administration and should be periodically monitored.
Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be
avoided. Patients should avoid food 2 hours before and 1 hour after taking
dose. A dose reduction is recommended in patients with hepatic impairment. ECGs
should be obtained to monitor the QTc at baseline, seven days after initiation,
and periodically thereafter, as well as following any dose adjustments.

DRUG DESCRIPTION



What are the possible side effects of nilotinib (Tasigna)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

dizziness and fast or pounding heartbeat;
shortness of breath;
swelling in your hands or feet;
seizure (convulsions);
warmth, redness, or tingly feeling under your skin;
nausea, loss of appetite, itching,...
Read All Potential Side Effects for Tasigna Capsules »




Tasigna (nilotinib) belongs to a pharmacologic class of drugs known as kinase
inhibitors.
Nilotinib drug substance, a monohydrate mono-hydrochloride, is a white to slightly
yellowish to slightly greenish yellow powder with the anhydrous molecular formula
and weight, respectively, of C28H22F3N7O•HCl•
H2O and 584. The solubility of nilotinib in aqueous solutions decreases
with increasing pH. Nilotinib is not optically active. The pKa1 was determined
to be 2.1; pKa2 was estimated to be 5.4.
The chemical name of nilotinib is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5­(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide,
monohydrochloride, monohydrate. Its structure is shown below:








 
Tasigna (nilotinib) capsules, for oral use, contain 150 mg or 200 mg nilotinib
base, anhydrous (as hydrochloride, monohydrate) with the following inactive
ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium
stearate and polyoxamer 188. The capsules contain gelatin, iron oxide (red),
iron oxide (yellow), iron oxide (black) and titanium dioxide.
Last reviewed on RxList: 7/12/2010




Tasigna Capsules Drug Description
Tasigna®
(nilotinib) Capsules

WARNING
QT PROLONGATION AND SUDDEN DEATHS
Tasigna prolongs the QT interval. Sudden deaths have been reported in patients
receiving nilotinib. Tasigna should not be used in patients with hypokalemia,
hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be
corrected prior to Tasigna administration and should be periodically monitored.
Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be
avoided. Patients should avoid food 2 hours before and 1 hour after taking
dose. A dose reduction is recommended in patients with hepatic impairment. ECGs
should be obtained to monitor the QTc at baseline, seven days after initiation,
and periodically thereafter, as well as following any dose adjustments.

DRUG DESCRIPTION



What are the possible side effects of nilotinib (Tasigna)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

dizziness and fast or pounding heartbeat;
shortness of breath;
swelling in your hands or feet;
seizure (convulsions);
warmth, redness, or tingly feeling under your skin;
nausea, loss of appetite, itching,...
Read All Potential Side Effects for Tasigna Capsules »




Tasigna (nilotinib) belongs to a pharmacologic class of drugs known as kinase
inhibitors.
Nilotinib drug substance, a monohydrate mono-hydrochloride, is a white to slightly
yellowish to slightly greenish yellow powder with the anhydrous molecular formula
and weight, respectively, of C28H22F3N7O•HCl•
H2O and 584. The solubility of nilotinib in aqueous solutions decreases
with increasing pH. Nilotinib is not optically active. The pKa1 was determined
to be 2.1; pKa2 was estimated to be 5.4.
The chemical name of nilotinib is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5­(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide,
monohydrochloride, monohydrate. Its structure is shown below:








 
Tasigna (nilotinib) capsules, for oral use, contain 150 mg or 200 mg nilotinib
base, anhydrous (as hydrochloride, monohydrate) with the following inactive
ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium
stearate and polyoxamer 188. The capsules contain gelatin, iron oxide (red),
iron oxide (yellow), iron oxide (black) and titanium dioxide.
Last reviewed on RxList: 7/12/2010




Tasigna Capsules Drug Description
Tasigna®
(nilotinib) Capsules

WARNING
QT PROLONGATION AND SUDDEN DEATHS
Tasigna prolongs the QT interval. Sudden deaths have been reported in patients
receiving nilotinib. Tasigna should not be used in patients with hypokalemia,
hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be
corrected prior to Tasigna administration and should be periodically monitored.
Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be
avoided. Patients should avoid food 2 hours before and 1 hour after taking
dose. A dose reduction is recommended in patients with hepatic impairment. ECGs
should be obtained to monitor the QTc at baseline, seven days after initiation,
and periodically thereafter, as well as following any dose adjustments.

DRUG DESCRIPTION



What are the possible side effects of nilotinib (Tasigna)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

dizziness and fast or pounding heartbeat;
shortness of breath;
swelling in your hands or feet;
seizure (convulsions);
warmth, redness, or tingly feeling under your skin;
nausea, loss of appetite, itching,...
Read All Potential Side Effects for Tasigna Capsules »




Tasigna (nilotinib) belongs to a pharmacologic class of drugs known as kinase
inhibitors.
Nilotinib drug substance, a monohydrate mono-hydrochloride, is a white to slightly
yellowish to slightly greenish yellow powder with the anhydrous molecular formula
and weight, respectively, of C28H22F3N7O•HCl•
H2O and 584. The solubility of nilotinib in aqueous solutions decreases
with increasing pH. Nilotinib is not optically active. The pKa1 was determined
to be 2.1; pKa2 was estimated to be 5.4.
The chemical name of nilotinib is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5­(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide,
monohydrochloride, monohydrate. Its structure is shown below:








 
Tasigna (nilotinib) capsules, for oral use, contain 150 mg or 200 mg nilotinib
base, anhydrous (as hydrochloride, monohydrate) with the following inactive
ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium
stearate and polyoxamer 188. The capsules contain gelatin, iron oxide (red),
iron oxide (yellow), iron oxide (black) and titanium dioxide.
Last reviewed on RxList: 7/12/2010




Tasigna Capsules Drug Description
Tasigna®
(nilotinib) Capsules

WARNING
QT PROLONGATION AND SUDDEN DEATHS
Tasigna prolongs the QT interval. Sudden deaths have been reported in patients
receiving nilotinib. Tasigna should not be used in patients with hypokalemia,
hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be
corrected prior to Tasigna administration and should be periodically monitored.
Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be
avoided. Patients should avoid food 2 hours before and 1 hour after taking
dose. A dose reduction is recommended in patients with hepatic impairment. ECGs
should be obtained to monitor the QTc at baseline, seven days after initiation,
and periodically thereafter, as well as following any dose adjustments.

DRUG DESCRIPTION



What are the possible side effects of nilotinib (Tasigna)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

dizziness and fast or pounding heartbeat;
shortness of breath;
swelling in your hands or feet;
seizure (convulsions);
warmth, redness, or tingly feeling under your skin;
nausea, loss of appetite, itching,...
Read All Potential Side Effects for Tasigna Capsules »




Tasigna (nilotinib) belongs to a pharmacologic class of drugs known as kinase
inhibitors.
Nilotinib drug substance, a monohydrate mono-hydrochloride, is a white to slightly
yellowish to slightly greenish yellow powder with the anhydrous molecular formula
and weight, respectively, of C28H22F3N7O•HCl•
H2O and 584. The solubility of nilotinib in aqueous solutions decreases
with increasing pH. Nilotinib is not optically active. The pKa1 was determined
to be 2.1; pKa2 was estimated to be 5.4.
The chemical name of nilotinib is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5­(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide,
monohydrochloride, monohydrate. Its structure is shown below:








 
Tasigna (nilotinib) capsules, for oral use, contain 150 mg or 200 mg nilotinib
base, anhydrous (as hydrochloride, monohydrate) with the following inactive
ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium
stearate and polyoxamer 188. The capsules contain gelatin, iron oxide (red),
iron oxide (yellow), iron oxide (black) and titanium dioxide.
Last reviewed on RxList: 7/12/2010




Tasigna Capsules Drug Description
Tasigna®
(nilotinib) Capsules

WARNING
QT PROLONGATION AND SUDDEN DEATHS
Tasigna prolongs the QT interval. Sudden deaths have been reported in patients
receiving nilotinib. Tasigna should not be used in patients with hypokalemia,
hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be
corrected prior to Tasigna administration and should be periodically monitored.
Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be
avoided. Patients should avoid food 2 hours before and 1 hour after taking
dose. A dose reduction is recommended in patients with hepatic impairment. ECGs
should be obtained to monitor the QTc at baseline, seven days after initiation,
and periodically thereafter, as well as following any dose adjustments.

DRUG DESCRIPTION



What are the possible side effects of nilotinib (Tasigna)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

dizziness and fast or pounding heartbeat;
shortness of breath;
swelling in your hands or feet;
seizure (convulsions);
warmth, redness, or tingly feeling under your skin;
nausea, loss of appetite, itching,...
Read All Potential Side Effects for Tasigna Capsules »




Tasigna (nilotinib) belongs to a pharmacologic class of drugs known as kinase
inhibitors.
Nilotinib drug substance, a monohydrate mono-hydrochloride, is a white to slightly
yellowish to slightly greenish yellow powder with the anhydrous molecular formula
and weight, respectively, of C28H22F3N7O•HCl•
H2O and 584. The solubility of nilotinib in aqueous solutions decreases
with increasing pH. Nilotinib is not optically active. The pKa1 was determined
to be 2.1; pKa2 was estimated to be 5.4.
The chemical name of nilotinib is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5­(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide,
monohydrochloride, monohydrate. Its structure is shown below:








 
Tasigna (nilotinib) capsules, for oral use, contain 150 mg or 200 mg nilotinib
base, anhydrous (as hydrochloride, monohydrate) with the following inactive
ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium
stearate and polyoxamer 188. The capsules contain gelatin, iron oxide (red),
iron oxide (yellow), iron oxide (black) and titanium dioxide.
Last reviewed on RxList: 7/12/2010





Other reviews about Nilotinib Capsules on wordpress

FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
  by Bishor
The U.S. Food and Drug Administration (FDA) has approved Tasigna (nilotinib) capsules for treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients whose disease has […]


Scottish Patients With Chronic Myeloid Leukaemia Gain Access To New Treatment
  by healtherm2
The Scottish Medicines Consortium (SMC) announced that Tasigna (nilotinib) is accepted for use within NHS Scotland for treatment of adult patients with Philadelphia positive (Ph+) chronic myelogenous leukaemia […]


Scottish Patients With Chronic Myeloid Leukaemia Gain Access To New Treatment
  by healtherm2
The Scottish Medicines Consortium (SMC) announced that Tasigna (nilotinib) is accepted for use within NHS Scotland for treatment of adult patients with Philadelphia positive (Ph+) chronic myelogenous leukaemia […]


You must go back, Koolau sa
  by dkyopmxmok
6:15 So the wall was finished in the twenty and fifth day of the month Elul, in fifty and two days. Having remained in the Persian court until […]


He mused over the cryptic wonder of it
  by qcipmzwrief
I stuck a pair of those diaphanous mirror sunglasses on my nose and strolled past him toward Dr. I wrote to you about it from America. The distant […]



Other reviews about Nilotinib Capsules on web:

All about Nilotinib Capsules. View complete and up to date Nilotinib information - part of the Drugs.com trusted medication database. Nilotinib Capsules Facts and Comparisons at Drugs.com


Learn about the prescription medication Tasigna Capsules (Nilotinib Capsules), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Tasigna Capsules (Nilotinib Capsules) Drug Information: Uses, Side ...


Paliperidone (Invega) Multum Quick Overview. Nilotinib capsules Tasigna ® FDA Approval: October 2007: Indication: Chronic myelogenous leukemia (chronic and accelerated phase Philadelphia ... Nilotinib (Tasigna)


Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor. It inhibits BCR-ABL. Uses. It was approved as Tasigna in the USA and the EU for drug ... Nilotinib - Wikipedia, the free encyclopedia


... (nilotinib) capsules Product Description Tasigna® (nilotinib) - Novartis Pharmaceuticals


Nilotinib is one of the most potent inhibitors of "wild-type KIT". It also is not affected ... The capsules should be swallowed whole with water. No food should be consumed for at ... Drug Details


On June 17, 2010, the U. S. Food and Drug Administration (FDA) granted accelerated approval to nilotinib (Tasigna ® Capsules, made by the Novartis Pharmaceuticals Corporation), an ... FDA Approval for Nilotinib - National Cancer Institute


Tasigna (nilotinib) 150-mg and 200-mg capsules from Novartis is a treatment for Ph+ Chronic Myeloid Leukemia in newly diagnosed adult patients in chronic phase or patients in ... CML (Chronic Myeloid Leukemia) Treatment – Find out if Tasigna ...


Nilotinib Pronunciation: (nye-LOE-ti-nib) Class: Protein tyrosine kinase inhibitor Trade Names: Tasigna - Capsules 200 mg Complete Nilotinib information from Drugs.com


A Medication Guide is required for distribution with Tasigna. Encourage patients to read the Tasigna Medication Guide. The complete text of the Medication Guide is reprinted at the ... Tasigna (nilotinib) Capsules Medication Guide





Featured Reviews

Reviews Leuprolide Acetate for Depot Suspension

Lupron Depot 11.25 mg Drug Description Lupron Depot (leuprolide acetate for depot suspension) Injection, Powder, Lyophilized, For Suspension DRUG DESCRIPTION What are the possible side effects of leuprolide (Eligard, Lupron, Lupron...
Read More  |  Review This
Reviews Tramadol Hcl

Ultram Drug Description ULTRAM® (tramadol hydrochloride) Tablets DRUG DESCRIPTION What are the possible side effects of tramadol (Ultram, Ultram ER)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Cyanocobalamin

CaloMist Nasal Spray Drug Description CaloMist Nasal Spray (cyanocobalamin, USP) DRUG DESCRIPTION What are the possible side effects of nasal cyanocobalamin (CaloMist, Nascobal)? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Adrenalin

Adrenalin Drug Description Adrenalin® Chloride Solution (epinephrine) Injection, USP 1:1000 DRUG DESCRIPTION What are the possible side effects of epinephrine ? Before using epinephrine a second time, tell your doctor if your...
Read More  |  Review This
Reviews Clobetasol Propionate Foam

Olux-E Drug Description Olux-E™ (clobetasol propionate) Foam, 0.05% Rx Only For Topical Use Only Not for Ophthalmic, Oral, or Intravaginal Use DRUG DESCRIPTION What are the possible side effects of clobetasol...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....